1.
Article
in English
| IMSEAR
| ID: sea-111421
ABSTRACT
A few years back, the survival benefit of trastuzumab in HER 2 positive breast cancer patients presenting with metastatic disease was proven in a randomized setting. Recently a number of randomized trials have reported their results in the adjuvant setting in HER 2 positive patients. These trials have been considered by some as a landmark in the evolution of breast cancer management. Although the data is encouraging, it need to be seen in a proper perspective keeping in mind the limitations and the side effects reported. This article stresses the use of Herceptin in carcinoma breast patients in adjuvant setting with a cautionary eye.
Subject(s)
Antibodies, Monoclonal/economics , Antineoplastic Agents/economics , Breast Neoplasms/drug therapy , Chemotherapy, Adjuvant , Female , Humans , Randomized Controlled Trials as Topic , Receptor, ErbB-2/drug effects
2.
Rev. argent. mastología
;
13(40): 79-82, jul. 1994.
Article
in Spanish
| LILACS
| ID: lil-180709